Abstract:Yi Liu, 1 David Quintanar Guerrero, 2 David Lechuga-Ballesteros, 3 Mingdian Tan, 1 Faiz Ahmad, 1 Bilal Aleiwi, 4 Edmund Lee Ellsworth, 4 Bin Chen, 4 Mei-Sze Chua, 1 Samuel So 1 1 Department of Surgery, School of Medicine, Stanford University, Stanford, CA, USA; 2 Laboratorio de Investigación y Posgrado en Tecnologías Farmacéuticas, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli, CP, 54745, Mexico; 3 AstraZeneca Pharmaceuticals, Ltd. 4222 Emperor Boulevard, Durham, NC, USA; 4 Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA Correspondence: Mei-Sze Chua, Email Introduction: We previously identified niclosamide as a promising repurposed drug candidate for hepatocellular carcinoma (HCC) treatment. However, it is poorly water soluble, limiting its tissue bioavailability and clinical application. To overcome these challenges, we developed an orally bioavailable self-microemulsifying drug delivery system encapsulating niclosamide (Nic-SMEDDS). Methods: Nic-SMEDDS was synthesized and characterized for its physicochemical properties, in vivo pharmacokinetics and absorption mechanisms, and in vivo therapeutic efficacy in an orthotopic patient-derived xenograft (PDX)-HCC mouse model. Niclosamide ethanolamine salt (NEN), with superior water solubility, was used as a positive control. Results: Nic-SMEDDS (5.6% drug load) displayed favorable physicochemical properties and drug release profiles in vitro. In vivo, Nic-SMEDDS displayed prolonged retention time and plasma release profile compared to niclosamide or NEN. Oral administration of Nic-SMEDDS to non-tumor bearing mice improved niclosamide bioavailability and C max by 4.1- and 1.8-fold, respectively, compared to oral niclosamide. Cycloheximide pre-treatment blocked niclosamide absorption from orally administered Nic-SMEDDS, suggesting that its absorption was facilitated through the chylomicron pathway. Nic-SMEDDS (100 mg/kg, bid) showed greater anti-tumor efficacy compared to NEN (200 mg/kg, qd); this correlated with higher levels ( p < 0.01) of niclosamide, increased caspase-3, and decreased Ki-67 in the harvested PDX tissues when Nic-SMEDDS was given. Biochemical analysis at the treatment end-point indicated that Nic-SMEDDS elevated lipid levels in treated mice. Conclusion: We successfully developed an orally bioavailable formulation of niclosamide, which significantly enhanced oral bioavailability and anti-tumor efficacy in an HCC PDX mouse model. Our data support its clinical translation for the treatment of solid tumors. Keywords: niclosamide, self-microemulsifying drug delivery system, SMEDDS, oral bioavailability, drug repurposing, hepatocellular carcinoma We previously used a bioinformatics approach to identify drugs (that have been approved by the Food and Drug Administration (FDA)), that can reverse the gene expression profiles of HCC cells to that of normal hepatocytes. Our efforts revealed niclosamide as top repurposing drug candidate for HCC treatment. 1 Niclosamide is an FDA-approved oral antiparasitic drug for treating tapeworm infection in humans. 2 In this capacity, it acts primarily by uncoupling oxidative phosphorylation in the mitochondria to impede metabolism. 3 Recent evidence indicates that niclosamide has a broad spectrum of action, including the inhibition of multiple signaling pathways that are critical in cancer cells. 4 Although in vitro data suggest encouraging anti-tumor effects in HCC, 1 colon cancer, 5 and prostate cancer, 6 subsequent animal studies and clinical trials in these cancer types have not been unsuccessful (NCT02687009; NCT03123978; NCT02807805; NCT02519582; NCT02532114). This is attributed to poor systemic exposure due to low water solubility and, consequently low bioavailability, preventing niclosamide from reaching the solid tumor sites. In order to achieve sufficiently high plasma concentrations required for anti-cancer effects, higher than approved doses of niclosamide are needed, which may lead to dose-limiting toxicities. 6,7 Although niclosamide failed to achieve significant anti-HCC efficacy in mouse models, its more water-soluble ethanolamine salt, niclosamide ethanolamine (NEN), significantly reduced the growth of an orthotopic HCC patient-derived xenograft (PDX) in mice. 1 This provided evidence that enhancing the water solubility of niclosamide is a practical approach to enhancing its anti-tumor efficacy in HCC. However, NEN is not FDA-approved for human use, prompting us to deve -Abstract Truncated-

Niclosamide Prodrug Enhances Oral Bioavailability and Targets Vasorin-TGFβ Signaling in Hepatocellular Carcinoma

Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma

Lipid-Based Self-Microemulsion of Niclosamide Achieved Enhanced Oral Delivery and Anti-Tumor Efficacy in Orthotopic Patient-Derived Xenograft of Hepatocellular Carcinoma in Mice

Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway

Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.

Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro, and In Vivo Evaluations

Antitumor effect and metabonomics of niclosamide micelles

Abstract 4479: Design, synthesis, and evaluation of amino acid conjugated niclosamide prodrugs as a PepT1 substrate

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

Optimizing Niclosamide for Cancer Therapy: Improving Bioavailability via Structural Modification and Nanotechnology

Injectable Pegylated Niclosamide (polyethylene Glycol-Modified Niclosamide) for Cancer Therapy

Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

A Reduction and Ph Dual-Sensitive Nanodrug for Targeted Theranostics in Hepatocellular Carcinoma

AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy

Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice

Inhalable chitosan-coated nano-assemblies potentiate niclosamide for targeted abrogation of non-small-cell lung cancer through dual modulation of autophagy and apoptosis

Niclosamide Acts As a New Inhibitor of Vasculogenic Mimicry in Oral Cancer Through Upregulation of Mir-124 and Downregulation of STAT3.

Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models

Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma.

Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers